This steroid-free, topical pan-Janus kinase (JAK) inhibitor is a new option for patients who have not responded adequately to other treatments or cannot use topical corticosteroids. Anzupgo works
The FDA has set a target action date of 6 March 2026. This regulatory step follows similar acceptances in China and Japan, as well as an application validation
This addresses symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patients with neurofibromatosis type 1 (NF1), starting from two years of age. Ezmekly is now the only
This designation is for its use in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. The FDA’s decision was
This expedited process is intended to hasten the development and review of new drugs that address serious conditions with unmet medical needs. The FDA established this procedure to
Leqselvi is an oral drug that selectively inhibits Janus kinases JAK1 and JAK2. It has been approved for adult patients experiencing severe forms of alopecia areata, an autoimmune
Golden Age Health (GAH) has secured exclusive rights to commercialise and promote Innostellar Biotherapeutics’ first-in-class gene therapy candidate, LX-101, in mainland China. This ten-year Promotional Services Agreement leverages
This partnership will combine the OligoCreator technology of Secarna with Vect-Horus’ VECTrans system. The alliance uses Vect-Horus’ expertise in delivering compounds across biological barriers using its VECTrans platform.
This application aims to secure approval for treating adult and adolescent atopic dermatitis (AD). Under the partnership agreement, Connect Biopharma will receive up to approximately $110m in milestone
The deal, valued at up to $25m, includes an upfront equity payment of $7.5m and near-term milestones, extending Rallybio’s cash runway into mid-2027. The REV102 programme originated from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.